U.S. GENETIC TESTING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The U.S. genetic testing market is estimated to be valued at USD 5,290.6 Mn in 2026 and is expected to reach USD 9,150.7 Mn by 2033, exhibiting a compound annual growth rate (CAGR) of 8.1% from 2026 to 2033. Genetic testing is a key segment in screening DNA, RNA, chromosomes, proteins, or metabolites to detect genetic mutations, genes, or chromosome alterations that cause or are related to inherited disorders. Genetic tests also analyze the susceptibility to certain diseases, help decide treatment for an individual and are sometimes used in legal settings or medical investigations. They are widely being incorporated into clinical diagnostics, reproductive health, oncology, orphan/rare diseases, and preventative care and screening programs.

Genetic testing services are sold through clinical and public diagnostic and counseling sites, hospitals, research institutions, and direct-to-consumer businesses, aiming to enable consumers to obtain meaningful insights from their genomic information and assist health care providers in making more targeted treatment decisions. The trend toward the adoption of genomic data in clinical care is paving the way for genetic tests to play a larger role in U.S. precision medicine.

Market Dynamics

The U.S. genetic testing market is primarily driven by the expanding applications of precision medicine; rising incidences of genetic disorders and cancer; and a surge in demand for early and accurate detection of diseases. Moreover, healthcare professionals are gradually adopting genetic testing for pre-screening of the predisposed disease, planning targeted therapies and personalized treatment management, due to constant development in next-generation sequencing technologies (NGS).

However, the growth of market is limited by factors such as high price of progressive genetic tests, low reimbursement for many tests, privacy and security concern over genetic data, and regulatory framework associated with tests validation, utility, and data processing. Nevertheless, there are abundant growth prospects due to factors such increasing access of consumer based genetic testing and integration of bioinformatics with genomic profiling. The availability of home-based testing systems and more proficient methods to interpret genomic variations also contribute to overall market growth in coming years.

Key Features of the Study

• This report provides in-depth analysis of the U.S. genetic testing market, and provides market size (USD Million) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the U.S. genetic testing market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Illumina, Quest Diagnostics, Labcorp Genetics, Natera, Myriad Genetics, GeneDx, Fulgent Genetics, Ambry Genetics, Exact Sciences, and 23andMe
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The U.S. genetic testing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the U.S. genetic testing market

Market Segmentation

• Offering Insights (Revenue, USD Mn, 2021 - 2033)
  • Products
  • Services
• Type of Testing Insights (Revenue, USD Mn, 2021 - 2033)
  • Single gene testing
  • Genetic testing panels
  • Large-scale genomic testing
  • Others
• Technology Insights (Revenue, USD Mn, 2021 - 2033)
  • Next Generation Sequencing (NGS)
  • PCR-Based Technologies
  • SNP Chip Technology
  • Supporting Technologies
• Application Insights (Revenue, USD Mn, 2021 - 2033)
  • Prenatal and Newborn Testing
  • Ancestry and Ethnicity Testing
  • Diagnostic Testing
  • Others
• End User Insights (Revenue, USD Mn, 2021 - 2033)
  • Hospitals
  • Independent and Diagnostic Laboratories
  • Academic and Research Institutes
  • Direct-to-Consumer
• Key Players Insights
  • Illumina, Inc.
  • Quest Diagnostics
  • Labcorp Genetics
  • Natera
  • Myriad Genetics
  • GeneDx
  • Fulgent Genetics
  • Ambry Genetics
  • Exact Sciences
  • 23andMe